In the most recent quarter, 55% of new Zepbound prescriptions at Eli Lilly were paid out-of-pocket, up from nearly 50% in the prior quarter. This heavy reliance on price-sensitive self-pay patients introduces revenue durability risks that could undermine the stock’s premium price-to-sales multiple of 14.
Eli Lilly reported that 55% of new prescriptions for its obesity drug Zepbound were paid out-of-pocket in the most recent quarter, up from nearly 50% previously. This shift highlights growing demand but also signals a reliance on non-insured patients.
Cash-paying patients face monthly purchasing decisions and are highly price-sensitive, making them prone to seeking cheaper alternatives or discontinuing treatment if finances change. This dynamic undermines revenue predictability compared to insured patients with formulary protections and co-pay structures.
The high self-pay mix challenges the durability of Zepbound’s revenue stream and calls into question the sustainability of Lilly’s premium valuation, currently at a 14 price-to-sales multiple. Investors may reassess growth assumptions if conversions to insured patients lag expectations.
